Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
Trial Details
- NCT ID
- NCT06553352
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- Non-Hodgkin Lymphoma Lymphoma
- Interventions
- Zanubrutinib combined with Obinutuzumab
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- Age: ≥18 years old and gender-neutral;
- Follicular lymphoma definitively diagnosed according to the REAL/WHO classification, stage II-IV requiring treatment according to the GELF code;
- ECOG score 0-2;
- Lymphoma efficacy evaluation criteria using Lugano 2014 Lymphoma must have at least one measurable or evaluable lesion: signed informed consent, su…
For full eligibility, visit ClinicalTrials.gov.